These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

620 related articles for article (PubMed ID: 28068603)

  • 41. Structure-based hybridization, synthesis and biological evaluation of novel tetracyclic heterocyclic azathioxanthone analogues as potential antitumor agents.
    Chen TC; Wu CL; Lee CC; Chen CL; Yu DS; Huang HS
    Eur J Med Chem; 2015 Oct; 103():615-27. PubMed ID: 25799376
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Novel N-4-piperazinyl-ciprofloxacin-chalcone hybrids: synthesis, physicochemical properties, anticancer and topoisomerase I and II inhibitory activity.
    Abdel-Aziz M; Park SE; Abuo-Rahma Gel-D; Sayed MA; Kwon Y
    Eur J Med Chem; 2013 Nov; 69():427-38. PubMed ID: 24090914
    [TBL] [Abstract][Full Text] [Related]  

  • 43. 3-(3-Butylamino-2-hydroxy-propoxy)-1-hydroxy-xanthen-9-one acts as a topoisomerase IIα catalytic inhibitor with low DNA damage.
    Park SE; Chang IH; Jun KY; Lee E; Lee ES; Na Y; Kwon Y
    Eur J Med Chem; 2013 Nov; 69():139-45. PubMed ID: 24013413
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Fluorinated 3,6,9-trisubstituted acridine derivatives as DNA interacting agents and topoisomerase inhibitors with A549 antiproliferative activity.
    Nunhart P; Konkoľová E; Janovec L; Jendželovský R; Vargová J; Ševc J; Matejová M; Miltáková B; Fedoročko P; Kozurkova M
    Bioorg Chem; 2020 Jan; 94():103393. PubMed ID: 31679839
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Fluorescein hydrazones: A series of novel non-intercalative topoisomerase IIα catalytic inhibitors induce G1 arrest and apoptosis in breast and colon cancer cells.
    Islam MS; Park S; Song C; Kadi AA; Kwon Y; Rahman AF
    Eur J Med Chem; 2017 Jan; 125():49-67. PubMed ID: 27654394
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Design, synthesis, and biological evaluation of 1,3-diarylisoquinolines as novel topoisomerase I catalytic inhibitors.
    Khadka DB; Park S; Jin Y; Han J; Kwon Y; Cho WJ
    Eur J Med Chem; 2018 Jan; 143():200-215. PubMed ID: 29174815
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Substituted 2-arylquinazolinones: Design, synthesis, and evaluation of cytotoxicity and inhibition of topoisomerases.
    Khadka DB; Tran GH; Shin S; Nguyen HT; Cao HT; Zhao C; Jin Y; Van HT; Chau MV; Kwon Y; Le TN; Cho WJ
    Eur J Med Chem; 2015 Oct; 103():69-79. PubMed ID: 26334499
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Design, synthesis and biological evaluation of novel perimidine o-quinone derivatives as non-intercalative topoisomerase II catalytic inhibitors.
    Zhou DC; Lu YT; Mai YW; Zhang C; Xia J; Yao PF; Wang HG; Huang SL; Huang ZS
    Bioorg Chem; 2019 Oct; 91():103131. PubMed ID: 31377387
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A novel indeno[1,2-b]pyridinone derivative, a DNA intercalative human topoisomerase IIα catalytic inhibitor, for caspase 3-independent anticancer activity.
    Jeon KH; Park C; Kadayat TM; Shrestha A; Lee ES; Kwon Y
    Chem Commun (Camb); 2017 Jun; 53(51):6864-6867. PubMed ID: 28604852
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Novel ciprofloxacin hybrids using biology oriented drug synthesis (BIODS) approach: Anticancer activity, effects on cell cycle profile, caspase-3 mediated apoptosis, topoisomerase II inhibition, and antibacterial activity.
    Kassab AE; Gedawy EM
    Eur J Med Chem; 2018 Apr; 150():403-418. PubMed ID: 29547830
    [TBL] [Abstract][Full Text] [Related]  

  • 51. 2,6-Dithienyl-4-furyl pyridines: Synthesis, topoisomerase I and II inhibition, cytotoxicity, structure-activity relationship, and docking study.
    Basnet A; Thapa P; Karki R; Choi H; Choi JH; Yun M; Jeong BS; Jahng Y; Na Y; Cho WJ; Kwon Y; Lee CS; Lee ES
    Bioorg Med Chem Lett; 2010 Jan; 20(1):42-7. PubMed ID: 19954977
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Synthesis, cytotoxicity and topoisomerase inhibition properties of multifarious aminoalkylated indeno[1,2-c]isoquinolin-5,11-diones.
    Ahn G; Schifano-Faux N; Goossens JF; Baldeyrou B; Couture A; Grandclaudon P; Lansiaux A; Ryckebusch A
    Bioorg Med Chem Lett; 2011 Apr; 21(8):2259-63. PubMed ID: 21439821
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Design, synthesis and antiproliferative evaluation of fluorenone analogs with DNA topoisomerase I inhibitory properties.
    Lee CC; Chang DM; Huang KF; Chen CL; Chen TC; Lo Y; Guh JH; Huang HS
    Bioorg Med Chem; 2013 Nov; 21(22):7125-33. PubMed ID: 24094433
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Design, efficient synthesis, docking studies, and anticancer evaluation of new quinoxalines as potential intercalative Topo II inhibitors and apoptosis inducers.
    Abbass EM; Khalil AK; Mohamed MM; Eissa IH; El-Naggar AM
    Bioorg Chem; 2020 Nov; 104():104255. PubMed ID: 32927130
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Synthesis and biological evaluation of C1-O-substituted-3-(3-butylamino-2-hydroxy-propoxy)-xanthen-9-one as topoisomerase IIα catalytic inhibitors.
    Park S; Hong E; Kwak SY; Jun KY; Lee ES; Kwon Y; Na Y
    Eur J Med Chem; 2016 Nov; 123():211-225. PubMed ID: 27484510
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Inhibition of DNA topoisomerases I and II and growth inhibition of HL-60 cells by novel acridine-based compounds.
    Janočková J; Plšíková J; Kašpárková J; Brabec V; Jendželovský R; Mikeš J; Kovaľ J; Hamuľaková S; Fedoročko P; Kuča K; Kožurková M
    Eur J Pharm Sci; 2015 Aug; 76():192-202. PubMed ID: 25960253
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Design, synthesis and biological evaluation of lapachol derivatives possessing indole scaffolds as topoisomerase I inhibitors.
    Zhang C; Qu Y; Niu B
    Bioorg Med Chem; 2016 Nov; 24(22):5781-5786. PubMed ID: 27667553
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Di-indenopyridines as topoisomerase II-selective anticancer agents: Design, synthesis, and structure-activity relationships.
    Shrestha A; Hwang SY; Kunwar S; Man Kadayat T; Park S; Liu Y; Jo H; Sheen N; Seo M; Lee ES; Kwon Y
    Bioorg Med Chem; 2023 Aug; 91():117403. PubMed ID: 37418826
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Design, synthesis and evaluation of 4-substituted anthra[2,1-c][1,2,5]thiadiazole-6,11-dione derivatives as novel non-camptothecin topoisomerase I inhibitors.
    Dong G; Fang Y; Liu Y; Liu N; Wu S; Zhang W; Sheng C
    Bioorg Med Chem Lett; 2017 May; 27(9):1929-1933. PubMed ID: 28351590
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Design, synthesis, molecular modeling and anti-proliferative evaluation of novel quinoxaline derivatives as potential DNA intercalators and topoisomerase II inhibitors.
    Ibrahim MK; Taghour MS; Metwaly AM; Belal A; Mehany ABM; Elhendawy MA; Radwan MM; Yassin AM; El-Deeb NM; Hafez EE; ElSohly MA; Eissa IH
    Eur J Med Chem; 2018 Jul; 155():117-134. PubMed ID: 29885574
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.